Wells Fargo Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)

Wells Fargo analyst maintained a Hold rating on DENTSPLY SIRONA yesterday and set a price target of $13.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

In addition to Wells Fargo, DENTSPLY SIRONA also received a Hold from Piper Sandler’s Jason Bednar in a report issued yesterday. However, on the same day, Barclays maintained a Sell rating on DENTSPLY SIRONA (NASDAQ: XRAY).

Based on DENTSPLY SIRONA’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $961 million and a GAAP net loss of $145 million. In comparison, last year the company earned a revenue of $905 million and had a GAAP net loss of $430 million

Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XRAY in relation to earlier this year. Most recently, in December 2025, Gregory Lucier, a Director at XRAY sold 82,200.00 shares for a total of $915,708.00.